group b streptococcus trivalent vaccine
Vaccineexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00678652)
Timeline
Indications
Mechanism of action
- Streptococcus sp. group BImmunity, active
Streptococcus sp. group B immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- group b streptococcus trivalent vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01446289 | Phase 2 | Sep 1, 2011 | Novartis, Regional Hospital Heilig Hart, Tienen, Belgium |
| NCT01412801 | Phase 2 | Sep 1, 2011 | Novartis |
| NCT01193920 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2010 | Novartis |
| NCT01150123 | Phase 1 | May 1, 2010 | GlaxoSmithKline, Novartis |
| NCT01053767 | Phase 1 | Jan 1, 2010 | Novartis |
| NCT01052935 | Phase 1 | Jan 1, 2010 | Novartis |
| NCT00678652 | Phase 1 | Apr 1, 2008 | United States Army |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 6 | 6 | 2 | 2010 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2010 |
| Regional Hospital Heilig Hart, Tienen, Belgium | Academic/Hospital | 1 | 0 | 1 | 2011 |
| United States Army | Government | 1 | 1 | 1 | 2008 |
4 organizations
Page 1 / 1